10-K: ENvue Medical Reports Financials, Faces Nasdaq Scrutiny

ENvue Medical, Inc. (formerly NanoVibronix, Inc.) filed its annual report detailing significant operational changes, including a merger and reverse stock splits, while addressing Nasdaq listing requirements and ongoing financial challenges.

Summary

• ENvue Medical, Inc. (formerly NanoVibronix, Inc.) has filed its annual report for the fiscal year ended December 31, 2025.
• The company underwent a significant merger on February 14, 2025, with ENvue Medical Holdings, Corp., subsequently changing its name.
• ENvue Medical operates through two subsidiaries: NanoVibronix Ltd. (focusing on pain therapy and wound healing devices) and ENvue Medical Holdings LLC (focused on enteral feeding devices).
• The company has implemented two reverse stock splits in 2025: a 1-for-11 split on March 13, 2025, and a 1-for-10 split on August 11, 2025.
• ENvue Medical has been actively raising capital through various offerings, including a registered direct offering in September 2025 and a private placement of Series H Convertible Preferred Stock in July 2025.
• The company is currently under mandatory panel monitoring by Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements, though it has demonstrated compliance as of April 2025.
• Significant increases in research and development (94%) and selling and marketing (246%) expenses were noted for 2025, contributing to a substantial increase in net loss to $18.2 million from $3.7 million in 2024.
• A goodwill and long-lived asset impairment charge of $11.2 million was recorded in 2025 related to the ENvue reporting unit.
• The company continues to face substantial doubt regarding its ability to continue as a going concern due to recurring losses and negative cash flows.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, sharp decline in gross margins, substantial operating expense growth, a large impairment charge, and the explicit statement of substantial doubt regarding the company's ability to continue as a going concern.

Positives

• Successful completion of the merger with ENvue Medical Holdings, Corp. on February 14, 2025.
• Demonstrated compliance with Nasdaq listing requirements as of April 2025, albeit under a one-year monitoring period.
• Secured significant capital through various equity financings in 2025, including a registered direct offering and a private placement, totaling over $10 million in net proceeds.
• The ENvue System has received FDA 510(k) clearance for marketing in the U.S. for adults aged 22 and over.
• NanoVibronix products (PainShield MD and UroShield) have received FDA clearance and CE Mark approval, respectively, in certain markets.
• The company has a portfolio of patents and pending applications protecting its technologies.
• Management is actively working to remediate material weaknesses in internal controls over financial reporting.

Negatives

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Net loss increased significantly to $18.2 million in 2025 from $3.7 million in 2024.
• Gross profit decreased by 90% in 2025, with gross margin falling to 6% from 59% in 2024, largely due to the removal of PainShield Ultra and inventory write-downs.
• Significant increases in operating expenses, particularly selling and marketing (246%) and general and administrative (121%), outpaced revenue growth.
• A substantial goodwill and long-lived asset impairment charge of $11.2 million was recognized in 2025.
• The company is subject to mandatory panel monitoring by Nasdaq for continued listing compliance.
• Material weaknesses in internal control over financial reporting were identified and remain unremediated as of December 31, 2025.
• The Protrade arbitration award of $1.5 million was affirmed by the appellate court, with the company accruing approximately $2.3 million including interest as of December 31, 2025.

Risks

• History of losses and expectation of continued losses, threatening long-term viability.
• Inability to raise additional capital could limit clinical trials and product development.
• Failure to obtain adequate reimbursement from third-party payers could limit market viability.
• Risk of product liability claims and potential inadequacy of insurance coverage.
• Uncertainty regarding the successful development and commercialization of product candidates.
• Potential for delisting from Nasdaq if continued listing requirements are not met.
• Dependence on the successful adoption and market acceptance of the ENvue System.
• Intense competition from established medical device companies with greater financial resources.
• Risks associated with operations in Israel, including political, economic, and military instability.
• Cybersecurity risks that could adversely affect business operations and data security.
• Potential for future sales of common stock upon exercise of warrants and options to dilute existing stockholders and depress stock price.
• The company's business and operations could suffer from computer system failures, cyber-attacks, or deficiencies in cybersecurity.
• The company's Israeli identity may negatively impact sales in certain markets.
• Fluctuations in foreign currency exchange rates and inflation could harm results of operations.

Future Outlook

The company expects to continue incurring losses and negative cash flows from operations. Its ability to continue operating is dependent on successfully marketing and selling its products and securing additional financing until profitability is achieved. Management has substantial doubt about the company's ability to continue as a going concern.

Management Comments

• Management has substantial doubt about our ability to continue as a going concern.
• We expect to continue to incur losses and negative cash flows from operations.
• We will need to raise additional capital to finance our losses, debt obligations, and negative cash flows from operations and may continue to be dependent on additional capital raising as long as our products do not reach commercial profitability.
• Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.

Industry Context

StockSavvy.ai notes that ENvue Medical operates in the competitive medical device sector, facing challenges common to early-stage companies, including significant R&D and marketing expenses, regulatory hurdles, and the need for continuous capital infusion. The company's dual focus on ultrasound-based pain/wound care and enteral feeding systems positions it in distinct but related healthcare markets.

Corporate Governance

Legal Proceedings

• The Protrade Systems, Inc. arbitration award of $1.5 million (plus interest) was affirmed by the Appellate Division of the Second Department on March 30, 2026. The company has accrued approximately $2.3 million, including interest, as of December 31, 2025.

Related Party Transactions

• Legal fees of $323,000 were paid to Pierson Ferdinand LLP in 2025, where a former board member, Aurora Cassirer, is a partner. Ms. Cassirer did not provide legal services to the company.
• Alpha Capital Anstalt, a significant shareholder, provided a $1.3 million convertible debenture (fully repaid in May 2025) and a $360 secured note (partially repaid, with a remaining balance of $1,080 as of December 31, 2025).
• Alpha Capital Anstalt also participated in the July 2025 private placement of Series H Preferred Stock and the September 2025 registered direct offering.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and the exercise of outstanding warrants and options.
• The company's ability to continue as a going concern poses a significant risk to all stakeholders.
• Investors may be concerned about the company's history of losses, increasing expenses, and unremediated material weaknesses in internal controls.
• The potential delisting from Nasdaq could negatively impact stock liquidity and investor confidence.
• Employees may be affected by the company's financial performance and the ongoing need for capital raises.

Next Steps

• Continue efforts to remediate material weaknesses in internal control over financial reporting.
• Monitor compliance with Nasdaq continued listing requirements.
• Seek additional capital to fund operations and product development.
• Focus on commercialization of the ENvue System and market acceptance.
• Evaluate the decision regarding the commercialization of the Nutriseal Nasogastric Aspiration Tube (NGAT).

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, with a substantial increase in net loss, a sharp decline in gross margins, and significant increases in operating expenses. The explicit statement of substantial doubt regarding its ability to continue as a going concern, coupled with unremediated material weaknesses in internal controls and ongoing Nasdaq listing scrutiny, presents a high-risk investment profile. While capital raises have occurred, they have not yet translated into profitability or operational stability. The significant impairment charges further underscore the challenges faced by the company.

Keywords

ENvue Medical, NanoVibronix, SEC Filing, Form 10-K, Annual Report, Medical Devices, Enteral Feeding, Pain Therapy, Ultrasound Technology, Merger, Reverse Stock Split, Nasdaq Listing, Capital Raise, Going Concern, Impairment Charge, Financial Results